Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Gibbs

Showing results (351-360 of 427) with videos related to

Pageof 43
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2023
A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) StudyLavinia Tan, Ben Tran, Jeanne Tie, et al.
Asia-Pacific Journal of Clinical Oncology|July 14, 2022
Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian populationImogen Walpole, Belinda Lee, Jeremy Shapiro, et al.
Asia-Pacific Journal of Clinical Oncology|January 24, 2022
Impact of the evolution in RAS mutation analysis in Australian patients with metastatic colorectal cancerChia Yuen Chong, Azim Jalali, Hui Li Wong, et al.
Clinical Colorectal Cancer|November 10, 2024
Initial Assessment of Resectability of Colorectal Cancer Liver Metastases Versus Clinical OutcomeGrace Y Kim, Azim Jalali, Grace Gard, et al.
Gut|February 1, 2018
Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomesDavid S Williams, Dmitri Mouradov, Robert N Jorissen, et al.
Cell Reports. Medicine|December 20, 2023
Unified framework for patient-derived, tumor-organoid-based predictive testing of standard-of-care therapies in metastatic colorectal cancerTao Tan, Dmitri Mouradov, Margaret Lee, et al.
International Journal of Cancer|January 3, 2013
MiRNA-362-3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancerLise Lotte Christensen, Heidi Tobiasen, Anja Holm, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2016
Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon CancerPradipta Ghosh, Jeanne Tie, Andrea Muranyi, et al.
The Lancet. Oncology|August 8, 2017
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trialsHarpreet S Wasan, Peter Gibbs, Navesh K Sharma, et al.
Journal of the National Cancer Institute|June 14, 2025
Association of non-steroidal anti-inflammatory medications and aspirin with colorectal cancer incidence in older adultsFarzana Y Zaman, Suzanne G Orchard, Galina Polekhina, et al.
Pageof 43

Showing results (351-360 of 427) with videos related to

Sort By:
Pageof 43
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2023
A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) StudyLavinia Tan, Ben Tran, Jeanne Tie, et al.
Asia-Pacific Journal of Clinical Oncology|July 14, 2022
Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian populationImogen Walpole, Belinda Lee, Jeremy Shapiro, et al.
Asia-Pacific Journal of Clinical Oncology|January 24, 2022
Impact of the evolution in RAS mutation analysis in Australian patients with metastatic colorectal cancerChia Yuen Chong, Azim Jalali, Hui Li Wong, et al.
Clinical Colorectal Cancer|November 10, 2024
Initial Assessment of Resectability of Colorectal Cancer Liver Metastases Versus Clinical OutcomeGrace Y Kim, Azim Jalali, Grace Gard, et al.
Gut|February 1, 2018
Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomesDavid S Williams, Dmitri Mouradov, Robert N Jorissen, et al.
Cell Reports. Medicine|December 20, 2023
Unified framework for patient-derived, tumor-organoid-based predictive testing of standard-of-care therapies in metastatic colorectal cancerTao Tan, Dmitri Mouradov, Margaret Lee, et al.
International Journal of Cancer|January 3, 2013
MiRNA-362-3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancerLise Lotte Christensen, Heidi Tobiasen, Anja Holm, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2016
Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon CancerPradipta Ghosh, Jeanne Tie, Andrea Muranyi, et al.
The Lancet. Oncology|August 8, 2017
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trialsHarpreet S Wasan, Peter Gibbs, Navesh K Sharma, et al.
Journal of the National Cancer Institute|June 14, 2025
Association of non-steroidal anti-inflammatory medications and aspirin with colorectal cancer incidence in older adultsFarzana Y Zaman, Suzanne G Orchard, Galina Polekhina, et al.
Pageof 43